The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

The EC has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic, Rxulti (brexpiprazole), for treating ...

AstraZeneca’s senior director in oncology data science outlined how the company uses AI for drug discovery at a recent talk.

Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement for drug targets' ...

Insilico Medicine has completed a Series E round, raising $110m to progress the development of its pipeline of drugs and AI ...

Atsena Therapeutics has received fast track designation from the FDA for ATSN-201, aimed at treating X-linked retinoschisis ...

Telix states its automated and high-throughput generator can produce sufficient lead-212 elution for up to 60 clinical doses, ...

Vivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug ...

The two companies are merging after previously filing for bankruptcy due to opioid-related litigation and financial losses.

Emergent has entered a strategic financial investment agreement with Swiss Rockets to support the latter’s biotech portfolio.

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.